Neuropathy induced by exogenously administered advanced glycation end-products in rats

Journal of Diabetes Investigation

Volumn 1, Issue 1-2, 2010, Pages 40-49

  Nishizawa, Yusuke ^a   Wada, Ryu ichi ^a   Baba, Masayuki ^b   Takeuchi, Masayoshi ^c   Hanyu Itabashi, Chieko ^a   Yagihashi, Soroku ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

Author keywords

Advanced glycation end products; Neuropathy; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; EDEMA; ENDOTHELIUM CELL; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; MOTOR NERVE CONDUCTION; NERVE CONDUCTION DISORDER; NERVE FUNCTION; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NERVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RAT; SCHWANN CELL;

EID: 79953762153     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2009.00002.x     Document Type: Article

References (41)

1. Vlassara H. Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 1994; 124: 19-30.
2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature Med 2001; 414: 813-820.
3. Sugimoto K, Nishizawa Y, Horiuchi S, et al. Localization in human diabetic peripheral nerve of Ne-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 1997; 40: 1380-1387.
4. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation end-products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403.
5. Haslbeck KM, Schleicher E, Bierhaus A, et al. The AGE/RAGE/NF-jB pathway may contribute to the pathogenesis of poly-neuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113: 288-291.
6. Bierhaus A, Haslbeck K-M, Humpert PM, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin family. J Clin Invest 2004; 114: 1741- 1751.
7. Toth C, Rong LL, Yang C, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008; 57: 1002-1017.
8. Takeuchi M, Makita Z, Yanagisawa K, et al. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med 1999; 5: 393-405.
9. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
10. Vlassara H, Fuh H, Makita Z, et al. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 1992; 89: 12043-12047.
11. Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704- 11708.
12. Ikeda K, Nagai R, Sakamoto T, et al. Immunochemical approaches to AGE-structures: characterization of anti-AGE antibodies. J Immunol Methods 1998; 215: 95-104.
13. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984; 81: 583-587.
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
15. Yagihashi S, Kamijo M, Baba M, et al. Effect of amino-guanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52.
16. +)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats. Diabetologia 1999; 42: 743-747.
17. Wada R, Nishizawa Y, Yagihashi N, et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-520.
18. Sugimoto K, Yagihashi S. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. Microvasc Res 1997; 53: 105- 112.
19. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev 1995; 11: 193-225.
20. Yagihashi S. Pathogenetic mechanisms of diabetic neuropathy: lessons from animal models. J Periph Nerv Syst 1997; 2: 113-132.
21. Sima AAF, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 1999; 42: 773-788.
22. Vlassara H, Fuh H, Donnelly T, et al. Advanced glycation end-products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbit. Mol Med 1995; 1: 447-456.
23. Raj DS, Choudhury D, Welbourne TC, et al. Advanced glyca-tion end products: a nephrologist's perspective. Am J Kidney Dis 2000; 35: 365-380.
24. Weiss MF, Erhard P, Kader-Attia FA, et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000; 57: 2571-2585.
25. Niwa T, Tsukushi S. 3-Deoxyglucosone and AGEs in uremic complications: inactivation of glutathione peroxidase by 3-deoxyglucosone. Kidney Int 2001; 78(Suppl.): S37-S41.
26. Bazzi C, Pagani C, Sorgato G, et al. Uremic polyneuropathy: a clinical and electrophysiological study in 135 short- and long-term hemodialyzed patients. Clin Nephrol 1991; 35: 176-181.
27. Ogura T, Makinodan A, Kubo T, et al. Electrophysiological course of uraemic neuropathy in haemodialysis patients. Postgrad Med J 2001; 77: 451-454.
28. Malberti F, Surian M, Farina M, et al. Effect of hemodialysis and hemodiafiltration on uremic neuropathy. Blood Purif 1991; 9: 285-295.
29. Takeuchi M, Makita Z, Bucala R, et al. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000; 6: 114-125.
30. Takeuchi M, Bucala R, Suzuki T, et al. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropath Exp Neurol 2000; 59: 1094-1105.
31. Sekido H, Suzuki T, Kato N, et al. Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. Biochem Biophys Res Commun 2004; 320: 241-248.
32. Yamamoto Y, Yonekura H, Watanabe T, et al. Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Prac 2007; 77(Suppl. 1): S30-S40.
33. Obrosova IG, van Huysen C, Fathallah L, et al. Evaluation of alpha (1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASB J 2000; 14: 1548-1558.
34. Cameron NE, Eaton SE, Cotter MA, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1977-1988.
35. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090-2095.
36. Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glycation end products (AGES) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 1994; 91: 8807-8811.
37. Wautier J-L, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperper-meability in diabetic rats. J Clin Invest 1996; 97: 238-243.
38. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
39. Kihara M, Schmelzer JD, Poduslo JF, et al. Aminoguanidine effect on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88: 6107-6111.
40. Cameron NE, Cotter MA, Dines K, et al. Effects of aminogua-nidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992; 35: 946-950.
41. Nah SS, Choi IY, Lee CK, et al. Effects of advanced glycation end products on the expression of COX-2, PGW2 and NO in human osteoarthritic chondrocytes. Rheumatology 2008; 47: 425-431.